RSS Feeds
Search

Companies

Companies

Displaying 11..20 of 98 - per page Previous page Next page
Order by
GW Pharmaceuticals
GW Pharmaceuticals develops a range of medicines based on cannabinoids and other controlled drugs More
LAWSON Business Development
LAWSON HEALTH RESEARCH INSTITUTE is one of Canada's largest hospital-based research institutes. More
Jelfa Pharmaceutical Company
Production, distribution and marketing of solid, semi-solid and injectable preparations. More
RAFARM
Development & Marketing of Pharmaceuticals for Human Use More
Rubicon Research Private Limited
Rubicon is a leading Drug Delivery company from India providing cost effective, world class product development solutions. We outlicense innovative products and offer contract research services. More
Lay Line Genomics
Lay Line Genomics S.p.A. (LLG) is a biopharmaceutical company focused on the discovery and development of innovative therapies for Alzheimer's and other neurological diseases. More
CeNeS Pharmaceuticals
CeNeS is a drug discovery and development company focused on clinically validated targets in pain, anaesthesia and CNS. More
AstraZeneca
Is committed to building on success, and the continued in-licensing of products and technologies is an acknowledged strategic priority More
Desitin Arzneimittel GmbH
Success in CNS More
NEURON BPh
NEURON BPh, one of the fastest growing Spanish Biotech Companies More
Displaying 11..20 of 98 - per page Previous page Next page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
Clinical Trial Recruitment in Central Nervous System Disorders - Highest Number of Patients were Recruited for Clinical Trials in Schizophrenia
Sep 2011 - 97 pages - $3,500
Other Central Nervous System Disorders Global Clinical Trials Review, Q1, 2011
Feb 2011 - 75 pages - $1,000
Deals and alliances in central nervous system diseases
Jun 2006 - 1068 pages - $2,495
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2010
Aug 2010 - 76 pages - $1,500
Emerging Technologies: Stem cells
Nov 2011 - 61 pages - $3,800
Central Nervous System Tumors Global Clinical Trial Review, Q4, 2010
Oct 2010 - 53 pages - $1,000
Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies
Feb 2011 - 209 pages - $3,500
Company Financials: Orexigen Therapeutics, Inc.
Jan 2010 - $75
Will 2011 Spell a Brighter Year for the Pharmaceutical Companies?
Mar 2011 - 6 pages - $500
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - December 2010
Dec 2010 - 68 pages - $1,000
More Related Market Research Reports >>>

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us